Target type: molecularfunction
Enables the calcium concentration-regulatable energy-independent passage of cations across a lipid bilayer down a concentration gradient. [GOC:dph, GOC:mtg_transport]
Calcium-activated cation channel activity is a molecular function that describes the ability of a protein to act as a channel that allows the passage of cations across a cell membrane, and whose opening is regulated by the binding of calcium ions. This activity is essential for a wide range of cellular processes, including neurotransmission, muscle contraction, and cellular signaling.
When calcium ions bind to the channel, they cause a conformational change in the protein that opens the pore, allowing cations to flow across the membrane. The specific cations that can pass through the channel vary depending on the type of channel, but typically include sodium, potassium, and calcium ions.
Calcium-activated cation channels are found in a variety of cell types, including neurons, muscle cells, and epithelial cells. They play important roles in regulating the electrical excitability of these cells, and in controlling the flow of ions across their membranes.
The molecular function of calcium-activated cation channel activity is a complex process that involves a number of different steps. These steps include:
* Binding of calcium ions to the channel protein.
* Conformational change in the channel protein, which opens the pore.
* Passage of cations through the pore.
* Closure of the pore, which is typically triggered by a decrease in calcium ion concentration.
Calcium-activated cation channels are regulated by a variety of factors, including:
* Calcium ion concentration.
* Voltage across the membrane.
* pH.
* Phosphorylation state of the channel protein.
These factors can modulate the activity of the channel, affecting the rate and direction of ion flow.
Disruptions in calcium-activated cation channel activity can lead to a number of diseases, including:
* Epilepsy.
* Muscular dystrophy.
* Cancer.
Further research into the molecular function of calcium-activated cation channel activity is crucial for understanding these diseases and developing new treatments.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Transient receptor potential cation channel subfamily M member 4 | A transient receptor potential cation channel subfamily M member 4 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8TD43] | Homo sapiens (human) |
| Anoctamin-1 | An anoctamin-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q5XXA6] | Homo sapiens (human) |
| Short transient receptor potential channel 3 | A short transient receptor potential cation channel TRPC3 that is encoded in the genome of human. [PRO:CNA, UniProtKB:Q13507] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| ym 58483 | |||
| clemizole | clemizole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a pyrrolidin-1-ylmethyl and a 4-chlorobenzyl groups at positions 2 and 1 respectively. clemizole: was heading 1966-94 (see under BENZIMIDAZOLES 1966-90); use BENZIMIDAZOLES to search CLEMIZOLE 1966-94; a histamine H1- blocker used to treat allergies | benzimidazoles; monochlorobenzenes; pyrrolidines | histamine antagonist |
| niclosamide | niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections. Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48) | benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide | anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor |
| 9-phenanthrol | 9-phenanthrol : A phenanthrol that is phenanthrene in which a hydrogen attached to a carbon in the central ring has been replaced by a hydroxy group. 9-phenanthrol: an inhibitor of AMP-dependent protein kinase catalytic subunit; structure in first source | phenanthrol | TRPM4 channel inhibitor |
| nitazoxanide | nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug | benzamides; carboxylic ester | |
| N-butyl-1H-benzimidazol-2-amine | benzimidazoles | ||
| 4-[3-(4-fluorophenyl)-2-methyl-7-oxo-1H-pyrazolo[1,5-a]pyrimidin-5-yl]-1-piperidinecarboxylic acid ethyl ester | pyrazoles; ring assembly | ||
| ethyl 1-(4-(2,3,3-trichloroacrylamido)phenyl)-5-(trifluoromethyl)-1h-pyrazole-4-carboxylate | ethyl 1-(4-(2,3,3-trichloroacrylamido)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate: structure in first source | ||
| n-((4-methoxy)-2-naphthyl)-5-nitroanthranilic acid | N-((4-methoxy)-2-naphthyl)-5-nitroanthranilic acid: inhibits anoctamin-1; structure in first source | ||
| t16ainh-a01 | T16AInh-A01: a TMEM16A inhibitor |